• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HDAC 抑制剂终于问世:CTCL 的染色质可及性特征。

HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

出版信息

Cancer Cell. 2017 Jul 10;32(1):1-3. doi: 10.1016/j.ccell.2017.06.008.

DOI:10.1016/j.ccell.2017.06.008
PMID:28697338
Abstract

In this issue of Cancer Cell, Qu et al. describe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of response and resistance to histone deacetylase inhibitor therapy. Their "personal regulome" analysis framework reveals chromatin features that may be predictive of clinical response to epigenetic therapy.

摘要

在本期《癌细胞》中,瞿等描述了皮肤 T 细胞淋巴瘤的染色质可及性图谱,并对组蛋白去乙酰化酶抑制剂治疗的反应和耐药进行了动态评估。他们的“个人调控组”分析框架揭示了可能预测表观遗传治疗临床反应的染色质特征。

相似文献

1
HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.HDAC 抑制剂终于问世:CTCL 的染色质可及性特征。
Cancer Cell. 2017 Jul 10;32(1):1-3. doi: 10.1016/j.ccell.2017.06.008.
2
Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.皮肤T细胞淋巴瘤的染色质可及性图谱及对组蛋白去乙酰化酶抑制剂的动态反应
Cancer Cell. 2017 Jul 10;32(1):27-41.e4. doi: 10.1016/j.ccell.2017.05.008. Epub 2017 Jun 15.
3
Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.新型细胞黏附/迁移途径是预测皮肤 T 细胞淋巴瘤中 HDAC 抑制剂耐药的标志物。
EBioMedicine. 2019 Aug;46:170-183. doi: 10.1016/j.ebiom.2019.07.053. Epub 2019 Jul 26.
4
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.组蛋白去乙酰化酶抑制剂治疗皮肤 T 细胞淋巴瘤。
Future Med Chem. 2012 Mar;4(4):471-86. doi: 10.4155/fmc.12.6.
5
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.皮肤T细胞淋巴瘤中异常IL15信号传导的机制、后果及治疗靶点
Cancer Discov. 2016 Sep;6(9):986-1005. doi: 10.1158/2159-8290.CD-15-1297. Epub 2016 Jul 15.
6
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.维甲酸与组蛋白去乙酰化酶抑制剂联合使用,通过组蛋白乙酰化恢复肿瘤抑制基因视黄酸受体β2,从而对皮肤T细胞淋巴瘤产生抗肿瘤作用。
J Dermatol Sci. 2016 Jan;81(1):17-25. doi: 10.1016/j.jdermsci.2015.10.016. Epub 2015 Oct 29.
7
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.组蛋白去乙酰化酶抑制剂帕比司他可诱导皮肤T细胞淋巴瘤出现临床反应,并伴有基因表达谱的相关改变。
Clin Cancer Res. 2008 Jul 15;14(14):4500-10. doi: 10.1158/1078-0432.CCR-07-4262.
8
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.组蛋白去乙酰化酶抑制剂SAHA与蛋白酶体抑制剂硼替佐米在皮肤T细胞淋巴瘤中的协同相互作用。
Eur J Haematol. 2009 Jun;82(6):440-9. doi: 10.1111/j.1600-0609.2009.01239.x. Epub 2009 Feb 10.
9
[HDAC inhibitor].[组蛋白去乙酰化酶抑制剂]
Nihon Rinsho. 2015 Feb;73 Suppl 2:277-80.
10
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.BCL11B介导的表观遗传抑制是皮肤T细胞淋巴瘤中组蛋白去乙酰化酶抑制剂的关键靶点。
J Invest Dermatol. 2017 Jul;137(7):1523-1532. doi: 10.1016/j.jid.2017.02.980. Epub 2017 Mar 10.

引用本文的文献

1
HDAC2-Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple-Negative Breast Cancer.HDAC2介导的METTL3去乙酰化促进三阴性乳腺癌的DNA损伤修复和化疗耐药性。
Adv Sci (Weinh). 2025 Apr;12(14):e2413121. doi: 10.1002/advs.202413121. Epub 2025 Feb 14.
2
Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers.使用染色质生物标志物检测 3D 癌症共培养物中的放射和化学耐药细胞。
Sci Rep. 2023 Nov 24;13(1):20662. doi: 10.1038/s41598-023-47287-2.
3
DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors .
DOT1L抑制不会改变皮肤T细胞淋巴瘤对泛组蛋白去乙酰化酶抑制剂的敏感性。
Front Genet. 2022 Nov 8;13:1032958. doi: 10.3389/fgene.2022.1032958. eCollection 2022.
4
Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma.表观遗传学在皮肤T细胞淋巴瘤发病机制及治疗中的作用
Front Oncol. 2021 Jun 24;11:663961. doi: 10.3389/fonc.2021.663961. eCollection 2021.
5
Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.在癌症治疗中表遗传学药物的预测生物标志物和潜在药物组合。
Clin Epigenetics. 2021 May 17;13(1):113. doi: 10.1186/s13148-021-01098-2.
6
CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.HDAC 抑制剂贝利司他诱导的 CXCL1 克隆进化可能是三阴性乳腺癌的有利预后指标。
Biomed Res Int. 2021 Apr 17;2021:5089371. doi: 10.1155/2021/5089371. eCollection 2021.
7
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.CD30 阳性原发性皮肤淋巴组织增生性疾病:分子改变与靶向治疗。
Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10.